168 related articles for article (PubMed ID: 9311444)
1. The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats.
Stehle G; Sinn H; Wunder A; Schrenk HH; Schütt S; Maier-Borst W; Heene DL
Anticancer Drugs; 1997 Aug; 8(7):677-85. PubMed ID: 9311444
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of methotrexate-albumin conjugates in tumor-bearing rats.
Stehle G; Wunder A; Sinn H; Schrenk HH; Schütt S; Frei E; Hartung G; Maier-Borst W; Heene DL
Anticancer Drugs; 1997 Oct; 8(9):835-44. PubMed ID: 9402310
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of an aminopterin-albumin conjugate in tumor-bearing rats.
Kremer P; Hartung G; Bauder-Wüst U; Schrenk HH; Wunder A; Heckl S; Zillmann U; Sinn H
Anticancer Drugs; 2002 Jul; 13(6):615-23. PubMed ID: 12172507
[TBL] [Abstract][Full Text] [Related]
4. Enhanced hepatocyte uptake and liver targeting of methotrexate using galactosylated albumin as a carrier.
Han JH; Oh YK; Kim DS; Kim CK
Int J Pharm; 1999 Oct; 188(1):39-47. PubMed ID: 10528081
[TBL] [Abstract][Full Text] [Related]
5. Albumin-based drug carriers: comparison between serum albumins of different species on pharmacokinetics and tumor uptake of the conjugate.
Stehle G; Wunder A; Schrenk HH; Hartung G; Heene DL; Sinn H
Anticancer Drugs; 1999 Sep; 10(8):785-90. PubMed ID: 10573211
[TBL] [Abstract][Full Text] [Related]
6. Altered pharmacokinetics and liver targetability of methotrexate by conjugation with lactosylated albumins.
Han J; Lim SJ; Lee MK; Kim CK
Drug Deliv; 2001; 8(3):125-34. PubMed ID: 11570592
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of methotrexate-albumin conjugates in rats bearing a Walker-256 carcinoma.
Wunder A; Stehle G; Schrenk HH; Hartung G; Heene DL; Maier-Borst W; Sinn H
Int J Cancer; 1998 Jun; 76(6):884-90. PubMed ID: 9626357
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate-albumin conjugate causes tumor growth delay in Dunning R3327 HI prostate cancer-bearing rats.
Stehle G; Wunder A; Schrenk HH; Hartung G; Heene DL; Sinn H
Anticancer Drugs; 1999 Apr; 10(4):405-11. PubMed ID: 10378676
[TBL] [Abstract][Full Text] [Related]
9. The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. III. Human serum albumin-methotrexate derivative, its preparation and basic testing.
Bures L; Bostík J; Motycka K; Spundová M; Rehák L
Neoplasma; 1988; 35(3):329-42. PubMed ID: 3405341
[TBL] [Abstract][Full Text] [Related]
10. Imaging tumor folate receptors using 111In-DTPA-methotrexate.
Ilgan S; Yang DJ; Higuchi T; Zareneyrizi F; Kim EE; Podoloff DA
Cancer Biother Radiopharm; 1998 Jun; 13(3):177-84. PubMed ID: 10850353
[TBL] [Abstract][Full Text] [Related]
11. Delivery of radionuclides to pretargeted monoclonal antibodies using dihydrofolate reductase and methotrexate in an affinity system.
Hawkins GA; McCabe RP; Kim CH; Subramanian R; Bredehorst R; McCullers GA; Vogel CW; Hanna MG; Pomato N
Cancer Res; 1993 May; 53(10 Suppl):2368-73. PubMed ID: 8485723
[TBL] [Abstract][Full Text] [Related]
12. Slow release properties and liver-targeting characteristics of methotrexate erythrocyte carriers.
Yuan SH; Ge WH; Huo J; Wang XH
Fundam Clin Pharmacol; 2009 Apr; 23(2):189-96. PubMed ID: 19298236
[TBL] [Abstract][Full Text] [Related]
13. Polyethylene glycol conjugates of methotrexate varying in their molecular weight from MW 750 to MW 40000: synthesis, characterization, and structure-activity relationships in vitro and in vivo.
Riebeseel K; Biedermann E; Löser R; Breiter N; Hanselmann R; Mülhaupt R; Unger C; Kratz F
Bioconjug Chem; 2002; 13(4):773-85. PubMed ID: 12121133
[TBL] [Abstract][Full Text] [Related]
14. Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis.
Wunder A; Müller-Ladner U; Stelzer EH; Funk J; Neumann E; Stehle G; Pap T; Sinn H; Gay S; Fiehn C
J Immunol; 2003 May; 170(9):4793-801. PubMed ID: 12707361
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
[TBL] [Abstract][Full Text] [Related]
16. Antitumor properties and toxicity of dextran-methotrexate conjugates are dependent on the molecular weight of the carrier.
Nevozhay D; Budzynska R; Kanska U; Jagiello M; Omar MS; Boratynski J; Opolski A
Anticancer Res; 2006; 26(2A):1135-43. PubMed ID: 16619515
[TBL] [Abstract][Full Text] [Related]
17. Mode of action of methotrexate-albumin in a human T-cell leukemia line and activity against an MTX-resistant clone.
Weigand M; Hartung G; Roboz J; Sieger S; Wolf M; Sinn H; Schrenk HH; Wiessler M; Frei E
Anticancer Drug Des; 2001; 16(4-5):227-37. PubMed ID: 12049481
[TBL] [Abstract][Full Text] [Related]
18. Influence of carrier on biodistribution and in vitro cytotoxicity of methotrexate-branched polypeptide conjugates.
Hudecz F; Clegg JA; Kajtár J; Embleton MJ; Pimm MV; Szekerke M; Baldwin RW
Bioconjug Chem; 1993; 4(1):25-33. PubMed ID: 8431509
[TBL] [Abstract][Full Text] [Related]
19. Lymphatic delivery and pharmacokinetics of methotrexate after intramuscular injection of differently charged liposome-entrapped methotrexate to rats.
Kim CK; Han JH
J Microencapsul; 1995; 12(4):437-46. PubMed ID: 8583318
[TBL] [Abstract][Full Text] [Related]
20. A micelle-like structure of poloxamer-methotrexate conjugates as nanocarrier for methotrexate delivery.
Ren J; Fang Z; Yao L; Dahmani FZ; Yin L; Zhou J; Yao J
Int J Pharm; 2015 Jun; 487(1-2):177-86. PubMed ID: 25865570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
